5 results on '"Bernal, Francisco"'
Search Results
2. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
- Author
-
Sánchez Ramírez, Javier, Morera Díaz, Yanelys, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Martín Bauta, Yenima, Selman-Housein Bernal, Katty-Hind, de la Torre Santos, Ana Victoria, Pérez de la Iglesia, Mariela, Trimiño Lorenzo, Lian, Team of Investigators of Compassionate use Program, Gavilondo Cowley, Jorge Víctor, Limonta Fernández, Miladys, Padrón Morales, Sheila, Leal Alpízar, Giselle, Godínez Díaz, Duneidis, Rodríguez Reinoso, José Luis, Melo Suárez, Grettel, Muzio González, Verena Lucila, López Carrazana, Luis J., and Carreño Rolando, Ihosvany Enrique
- Subjects
IMMUNOTHERAPY ,CANCER patients ,VASCULAR endothelial growth factors ,IMMUNE serums ,VASCULAR endothelial growth factor receptors ,CANCER vaccines - Abstract
Background: CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterially-derived adjuvant VSSP. CIGB-247 has been already evaluated in two phase I clinical trials (CENTAURO and CENTAURO-2), showing to be safe and immunogenic in advanced cancer patients selected under well-defined and controlled clinical conditions. Surviving patients were submitted to monthly re-immunizations and some of them showed objective clinical benefits. Based on these results, a compassionate use program (CUP) with CIGB-247 was initiated for patients that did not meet the strict entry criteria applied for the CENTAURO and CENTAURO-2 clinical trials, but could potentially benefit from the application of this cancer therapeutic vaccine. Results: Polyclonal IgM, IgA and IgG antibodies specific for VEGF were detected by ELISA in serum samples from patients vaccinated with 400 μg of antigen combined with 200 μg of VSSP. Polyclonal antibody response showed no cross reactivity for other VEGF family member molecules like VEGF-C and VEGF-D. Serum from immunized individuals was able to block the binding of VEGF to its receptors VEGFR2 and VEGFR1. IgG fraction purified from immune sera shared the aforementioned characteristics and also inhibited the interaction between VEGF and the therapeutic recombinant antibody bevacizumab, an anti-angiogenic drug approved for the treatment of different tumors. No serious adverse events attributable to CIGB-247 have been documented yet in participants of the CIGB-247 CUP. The present paper is a first report of our findings concerning the humoral response and safety characteristics in treated CIGB-247 CUP cancer patients. The study has provided the unique opportunity of not only testing CIGB-247 in a broader clinical spectrum sample of Cuban cancer patients, but also within the context of the day-to-day clinical practice and treatment settings for these diseases in Cuban medical institutions. Conclusions: The CIGB-247 CUP has demonstrated that immunization and follow-up of a variety of cancer patients, under day-to-day clinical practice conditions in several Cuban medical institutions, replicate our previous findings in clinical trials: CIGB-247 is safe and immunogenic. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
- Author
-
Ramírez, Javier Sánchez, Díaz, Yanelys Morera, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Bernal, Katty-Hind Selman-Housein, de la Torre Santos, Ana, Álvarez, Eduardo Rafael Santiesteban, Bauta, Yenima Martín, Badell, Cimara H. Bermúdez, de la Torre Pupo, Josué, and Gavilondo, Jorge V.
- Subjects
TUMORS ,HUMORAL immunity ,IMMUNOTHERAPY ,TUMOR treatment ,VASCULAR endothelial growth factor receptors ,BIOAVAILABILITY ,PATIENTS - Abstract
Background: CIGB-247, a VSSP-adjuvanted VEGF-based vaccine, was evaluated in a phase I clinical trial in patients with advanced solid tumors (CENTAURO). Vaccination with the maximum dose of antigen showed an excellent safety profile, exhibited the highest immunogenicity and was the only one showing a reduction on platelet VEGF bioavailability. However, this antigen dose level did not achieve a complete seroconversion rate in vaccinated patients. These clinical results led us to the question whether a "reserve" of untapped immune response potential against VEGF could exist in cancer patients. To address this matter, CENTAURO-2 clinical trial was conducted where antigen and VSSP dose scale up were studied, and also incorporated the exploration of aluminum phosphate as adjuvant. These changes were made with the aim to increase immune response against VEGF. Results: The present study reports the characterization of the humoral response elicited by CIGB-247 from the combining of different antigen doses and adjuvants. Cancer patients were immunologically monitored for approximately 1 year. Vaccination with different CIGB-247 formulations exhibited a very positive safety profile. Cancer patients developed IgM, IgG or IgA antibodies specific to VEGF. Elicited polyclonal antibodies had the ability to block the interaction between VEGF and its receptors, VEGFR1 and VEGFR2. The highest humoral response was detected in patients immunized with 800 μg of antigen + 200 µg of VSSP. Off-protocol long-term vaccination did not produce negative changes in humoral response. Conclusions: Vaccination with a human VEGF variant molecule as antigen in combination with VSSP or aluminum phosphate is immunogenic. The results of this study could contribute to the investigation of this vaccine therapy in an adequately powered efficacy trial. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.
- Author
-
Betancourt, Blas Y, Marrero-Miragaya, María A, Jiménez-López, Giset, Valenzuela-Silva, Carmen, García-Iglesias, Elizeth, Hernández-Bernal, Francisco, Debesa-García, Francisco, González-López, Tania, Alvarez-Falcón, Leovaldo, and López-Saura, Pedro A
- Subjects
MYOCARDIAL infarction ,CORONARY disease ,CLINICAL trials ,MEDICAL experimentation on humans ,DRUG side effects ,MEDICAL research - Abstract
Background: Streptokinase (SK) is an effective fibrinolytic agent for the treatment of acute myocardial infarction (AMI). The objective of the present study was to assess the adverse drug reactions (ADRs) associated with intravenous recombinant SK in patients with AMI in routine clinical practice. Methods: A national, prospective and spontaneous reporting-based pharmacovigilance program was conducted in Cuba. Patient demographics, suspected ADR description, elements to define causality, and outcomes were documented and analyzed. Results: A total of 1496 suspected ADRs identified in 792 patients out of the 1660 (47.7 %) prescriptions reported in the program, were received from July 1995 to July 2002. Most of the patients (71.3%) were male, 67.2% were white and mean age was 61.6 ± 13.0 years. The mean time interval between the onset of symptoms and the start of the SK infusion was 4.9 ± 3.7 h. The most frequently reported ADRs were hypotension, arrhythmias, chills, tremors, vomiting, nauseas, allergy, bleeding and fever. ADR severity was 38% mild, 38% moderate, 10% severe, and 4% very severe. Only 3 patients with hemorrhagic stroke were reported. Seventy-two patients died in-hospital mainly because of cardiac causes associated with the patient's underlying clinical condition. Mortality was 3 times more likely in patients suffering arrhythmias than in those without this event (odds ratio 3.1, 95% CI: 1.8 to 5.1). Most of the reported ADRs were classified as possibly or probably associated with the study medication. Conclusion: Recombinant SK was associated with a similar post-marketing safety profile to those suggested in previous clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
5. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
- Author
-
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Selman-Housein Bernal KH, de la Torre Santos A, Santiesteban Álvarez ER, Martín Bauta Y, Bermúdez Badell CH, de la Torre Pupo J, Gavilondo JV, and Ayala Avila M
- Subjects
- Animals, Antigens, Neoplasm administration & dosage, Antigens, Neoplasm immunology, Cancer Vaccines administration & dosage, Chlorocebus aethiops, Female, Humans, Immunity, Humoral drug effects, Immunoglobulin G blood, Immunoglobulin G immunology, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms blood, Rabbits, Receptors, Vascular Endothelial Growth Factor blood, Receptors, Vascular Endothelial Growth Factor metabolism, Recombinant Proteins administration & dosage, Recombinant Proteins immunology, Treatment Outcome, Vascular Endothelial Growth Factor A metabolism, Adjuvants, Immunologic administration & dosage, Cancer Vaccines immunology, Immunity, Humoral immunology, Immunotherapy, Active, Neoplasms immunology, Neoplasms therapy, Vascular Endothelial Growth Factor A immunology
- Abstract
Background: CIGB-247, a VSSP-adjuvanted VEGF-based vaccine, was evaluated in a phase I clinical trial in patients with advanced solid tumors (CENTAURO). Vaccination with the maximum dose of antigen showed an excellent safety profile, exhibited the highest immunogenicity and was the only one showing a reduction on platelet VEGF bioavailability. However, this antigen dose level did not achieve a complete seroconversion rate in vaccinated patients. These clinical results led us to the question whether a "reserve" of untapped immune response potential against VEGF could exist in cancer patients. To address this matter, CENTAURO-2 clinical trial was conducted where antigen and VSSP dose scale up were studied, and also incorporated the exploration of aluminum phosphate as adjuvant. These changes were made with the aim to increase immune response against VEGF., Results: The present study reports the characterization of the humoral response elicited by CIGB-247 from the combining of different antigen doses and adjuvants. Cancer patients were immunologically monitored for approximately 1 year. Vaccination with different CIGB-247 formulations exhibited a very positive safety profile. Cancer patients developed IgM, IgG or IgA antibodies specific to VEGF. Elicited polyclonal antibodies had the ability to block the interaction between VEGF and its receptors, VEGFR1 and VEGFR2. The highest humoral response was detected in patients immunized with 800 μg of antigen + 200 μg of VSSP. Off-protocol long-term vaccination did not produce negative changes in humoral response., Conclusions: Vaccination with a human VEGF variant molecule as antigen in combination with VSSP or aluminum phosphate is immunogenic. The results of this study could contribute to the investigation of this vaccine therapy in an adequately powered efficacy trial., Trial Registration: Trial registration number: RPCEC00000155. Cuban Public Clinical Trial Registry. Date of registration: June 06, 2013. Available from: http://registroclinico.sld.cu/ .
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.